Tracer library / [18F]FMN3PA

[18F]FMN3PA

Also written as [18F]FMN3PA; [F-18]FMN3PA

Radionuclide: F-18 t½ 109.77 min
Modality: PET
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Parkinsonian syndromes and movement disorders

What it is

Compound class: LRRK2 kinase inhibitor
Target / mechanism: Leucine-rich repeat kinase 2 (LRRK2) PMID 33248850
Clinical application: Parkinson's disease (LRRK2 G2019S mutation-related) PMID 33248850
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
TRACERlab FX N GE HealthCare	—	SPE	37 ± 1.6%	≥96%	—	33248850 2021 Eur J Med Chem Radiosyntheses of [18F]FMN3PA (14) and [18F]FMN3PU (15) were performed using K[18F]-F-K222 complex in a TRACERlab FXN module - 37 ± 1.6% (n = 6) ([18F]FMN3PA, 14)

Need this precursor?We can point you to suppliers for [18F]FMN3PA, or handle the enquiry for you.

Get in touch

Quality control Preliminary - inferred from compound class

Ph. Eur. monograph: not verified No Ph. Eur. check is recorded for this entry.
USP monograph: not verified No USP check is recorded for this entry.

AppearancepHRCP HPLCRCP TLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrity

How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary); conventional nucleophilic 18F-fluorination assumed from isotope/compound class, no synthesis data confirming K222 use -> Kryptofix test (preliminary)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [18F]FMN3PA.

Get in touch

Notes

Added from reverse module search (stage 6); 1 article(s) with F-18. Stage set/updated at stage 39 from PMID 33248850: 'Dynamic scans by PET/CT (Siemens Inveon) were performed in WT mice (n = 3).'.